Entellus Medical Inc (NASDAQ:ENTL) was the recipient of a large drop in short interest in December. As of December 29th, there was short interest totalling 471,791 shares, a drop of 42.1% from the December 15th total of 815,374 shares. Approximately 3.2% of the shares of the stock are short sold. Based on an average trading volume of 134,223 shares, the short-interest ratio is presently 3.5 days.
Entellus Medical (NASDAQ ENTL) opened at $24.04 on Friday. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32. Entellus Medical has a 1 year low of $11.47 and a 1 year high of $25.58. The company has a market capitalization of $612.65 and a PE ratio of -18.78.
Entellus Medical (NASDAQ:ENTL) last posted its quarterly earnings results on Wednesday, November 1st. The medical technology company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.02. Entellus Medical had a negative return on equity of 47.37% and a negative net margin of 31.24%. sell-side analysts anticipate that Entellus Medical will post -1.33 earnings per share for the current fiscal year.
ENTL has been the topic of several recent research reports. William Blair lowered Entellus Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, December 8th. ValuEngine upgraded Entellus Medical from a “sell” rating to a “hold” rating in a research report on Thursday, December 7th. Zacks Investment Research lowered Entellus Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, October 31st. TheStreet upgraded Entellus Medical from a “d” rating to a “c-” rating in a research report on Thursday, December 14th. Finally, Canaccord Genuity reiterated a “hold” rating and set a $17.00 price objective on shares of Entellus Medical in a research report on Tuesday, October 17th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. Entellus Medical currently has a consensus rating of “Hold” and an average price target of $19.25.
In other Entellus Medical news, VP Thomas P. Williamson sold 2,449 shares of the firm’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $24.08, for a total value of $58,971.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Robert S. White sold 3,471 shares of the firm’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $24.01, for a total value of $83,338.71. The disclosure for this sale can be found here. In the last ninety days, insiders sold 108,942 shares of company stock worth $2,599,658. Insiders own 7.70% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Archon Capital Management LLC grew its position in Entellus Medical by 14.9% during the 3rd quarter. Archon Capital Management LLC now owns 550,224 shares of the medical technology company’s stock worth $10,157,000 after acquiring an additional 71,404 shares during the last quarter. Aisling Capital LLC bought a new position in Entellus Medical during the 3rd quarter worth approximately $9,759,000. First Light Asset Management LLC grew its position in Entellus Medical by 25.7% during the 2nd quarter. First Light Asset Management LLC now owns 512,416 shares of the medical technology company’s stock worth $8,486,000 after acquiring an additional 104,919 shares during the last quarter. Vanguard Group Inc. grew its position in Entellus Medical by 14.2% during the 2nd quarter. Vanguard Group Inc. now owns 485,294 shares of the medical technology company’s stock worth $8,036,000 after acquiring an additional 60,471 shares during the last quarter. Finally, Tekla Capital Management LLC bought a new position in Entellus Medical during the 2nd quarter worth approximately $5,655,000. Institutional investors and hedge funds own 78.24% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/20/short-interest-in-entellus-medical-inc-entl-drops-by-42-1.html.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.